1218 results found
In 2017–18, almost 1 million Australian adults had type 2 diabetes (T2D) and, in 2018, diabetes contributed to 11% of, or over 17,000, Australian deaths.1,2 Cardiovascular disease is the primary cause of death for people with diabetes and obesity is a major contributor to the disease.3
NHMRC recognises excellence in the health and medical research sector through its annual Research Excellence Awards. Find our 2023 award winners listed below.
NHMRC opened a Targeted Call for Research (TCR) into Debilitating Symptom Complex Attributed to Ticks on 30 May 2018. Given the public interest in the call following the Senate Inquiry and the government’s response to fund further research on this issue, NHMRC decided to re-open the call to accept additional applications to ensure that a breadth of the highest quality research is funded. The extended call for applications closed on 29 August 2018.
National Health and Medical Research Council (NHMRC) has established an advisory committee to seek advice on Aboriginal and Torres Strait Islander health and health research issues.
CEO Communique – February 2022
The Targeted Call for Research (TCR): Improving infection prevention and control in residential aged care homes 2023 grant opportunity aims to inform evidence-based interventions for the implementation of infection prevention and control (IPC) programs and support IPC leads in public and private residential aged care homes across Australia.
Consultation on options to reach gender equity in the Investigator Grant scheme: Consultation closed
NHMRC's vision is a gender diverse and inclusive health and medical research workforce to take advantage of the full range of talent needed to build a healthy Australia. NHMRC has completed its consultation on options to reach gender equity in the NHMRC Investigator Grant scheme.
Leukaemias are difficult-to-treat blood cancers, which are common among both young and older people. In Australia in 2023, around 20,000 people were diagnosed with a blood cancer and blood cancers accounted for an estimated 38% of all cancer cases among the 0–19 year-old age group. Over 5,000 Australians die each year from blood cancers.1 NHMRC-funded researchers at WEHI have made revolutionary breakthroughs in our understanding of leukaemia biology, leading to the development of a new type of anti-cancer drug, venetoclax, that has significantly improved treatment for leukaemia patients.